The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Oliushina E.M.

Russian Medical Academy of Continuous Professional Education

Byakhova M.M.

Russian Medical Academy for Continuous Professional Education;
Vladimirsky Moscow Regional Research Clinical Institute

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Semenova A.B.

City Clinical Oncology Hospital No. 1

Frank G.A.

Russian Medical Academy of Continuous Professional Education

The role of the immunohistochemical marker p40 in the differential diagnosis of adenocarcinoma and nonkeratinizing squamous cell cancer of the lung

Authors:

Oliushina E.M., Byakhova M.M., Zavalishina L.E., Andreeva Yu.Yu., Semenova A.B., Frank G.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2020;82(5): 50‑56

DOI: 10.17116/patol20208205150

Read: 16010 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF THE IMMUNOHISTOCHEMICAL MARKER P40 IN THE DIFFERENTIAL DIAGNOSIS OF ADENOCARCINOMA AND NONKERATINIZING SQUAMOUS CELL CANCER OF THE LUNG
THE ROLE OF THE IMMUNOHISTOCHEMICAL MARKER P40 IN THE DIFFERENTIAL DIAGNOSIS OF ADENOCARCINOMA AND NONKERATINIZING SQUAMOUS CELL CANCER OF THE LUNG

To cite this article:

Oliushina EM, Byakhova MM, Zavalishina LE, Andreeva YuYu, Semenova AB, Frank GA. The role of the immunohistochemical marker p40 in the differential diagnosis of adenocarcinoma and nonkeratinizing squamous cell cancer of the lung. Russian Journal of Archive of Pathology. 2020;82(5):50‑56. (In Russ.)
https://doi.org/10.17116/patol20208205150

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Morphological examination of surgical mate­rial of primary lung cancer after neoadjuvant therapy: reco­mmendations and lite­rature review. Russian Journal of Archive of Pathology. 2025;(4):40-46
Hete­rogeneity of ALDH1, CD133 and CD34 expression in cancer stem cells of lung adenocarcinoma. Russian Journal of Archive of Pathology. 2025;(5):36-45
Features of lung cancer carcinogenesis invo­lving cancer stem cells in COVID-19. Effe­cts of photodynamic therapy in the treatment of cancer and COVID-19. Russian Journal of Archive of Pathology. 2025;(5):65-73
The first thousand of VATS anatomical lung rese­ctions at the Herzen Moscow Onco­logy Research Institute. Piro­gov Russian Journal of Surgery. 2025;(6):7-18
Prognostic model and calculator for asse­ssing the risk of prolonged pleural effu­sion after lobe­ctomy. Piro­gov Russian Journal of Surgery. 2025;(6):26-34
Fibrosing inte­rstitial lung disease as a risk factor for lung cancer: a review of the lite­rature and clinical case report. Journal of Respiratory Medi­cine. 2025;(2):51-59
Survival of patients with mali­gnant lung neoplasms in the Tomsk region (2013—2022). Russian Journal of Preventive Medi­cine. 2025;(7):43-49
Video-assisted mediastinal lymphadenectomy in the treatment stra­tegy of patients with non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(5):13-18
Pulmonary artery surgery in thoracic onco­logy. Piro­gov Russian Journal of Surgery. 2025;(10):24-30
Prediction of mediastinal nodal meta­stases based on multivariate analysis of VAMLA resu­lts in non-small cell lung cancer patients. Piro­gov Russian Journal of Surgery. 2025;(10):38-46
Abstract:

Lung cancer is one of the main causes of cancer death. It is a heterogeneous group of malignant neoplasms, the treatment tactics for which directly depends on tumor morphology and genetic characteristics. However, the pathomorphological differential diagnosis of adenocarcinoma and squamous cell cancer of the lung is difficult in some cases and an immunohistochemical (IHC) study is needed to verify these tumors; moreover, the IHC panel should include both squamous cell and pneumocyte markers. Fifty surgical and biopsy specimens underwent morphological and IHC studies using antibodies against p40, p63, CK5/6, CK7, and TTF1. In this investigation, p40 showed a higher specificity than another squamous cell differentiation marker, such as p63; this confirms the data that it is advisable to use the marker p40 to verify squamous cell lung carcinoma. If there is a small amount of material for an IHC study in the differential diagnosis of adenocarcinoma from squamous cell cancer of the lung, the optimal solution is to limit the IHC panel to two markers, such as p40 and TTF1.

Keywords:

lung cancer
lung adenocarcinoma
nonkeratinizing squamous cell lung cancer
p40 expression

Authors:

Oliushina E.M.

Russian Medical Academy of Continuous Professional Education

Byakhova M.M.

Russian Medical Academy for Continuous Professional Education;
Vladimirsky Moscow Regional Research Clinical Institute

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

Andreeva Yu.Yu.

Russian Medical Academy of Continuous Professional Education

Semenova A.B.

City Clinical Oncology Hospital No. 1

Frank G.A.

Russian Medical Academy of Continuous Professional Education

Received:

12.05.2020

Accepted:

19.06.2020

Close metadata

References:

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.  https://doi.org/10.3322/caac.21262
  2. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S. ESMO Guidelines Committee. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):1-27.  https://doi.org/10.1093/annonc/mdw326
  3. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: a review of two-Phase III studies. Oncologist. 2009;14(3):253-263.  https://doi.org/10.1634/theoncologist.2008-0232
  4. Gorbunova VA, Artamonova EV, Breder VV, Laktionov KK, Moiseenko FV, Reutova EV, Sakaeva DD. Practical guidelines for the treatment of non-small cell lung cancer. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO. 2017;7(3, Suppl 2):28-42. (In Russ.) https://doi.org/10.18027/2224-5057-2017-7-3s2-28-42
  5. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(9):911-9119. https://doi.org/10.1200/JCO.2017.76.7293
  6. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of tumours of lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015.
  7. Koh J, Go H, Kim MY, Jeon YK, Chung JH, Chung DH. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. Histopathology. 2014;65(6):868-878.  https://doi.org/10.1111/his.12507
  8. Affandi KA, Tizen NMS, Mustangin M, Zin RRMRM. p40 Immunohistochemistry is an excellent marker in primary lung squamous cell carcinoma. J Pathol Transl Med. 2018;52(5):283-289.  https://doi.org/10.4132/jptm.2018.08.14
  9. Nobre AR, Albergaria A, Schmitt F. A p63 isoform useful for lung cancer diagnosis — a review of the physiological and pathological role of p63. Acta Cytol. 2013;57(1):1-8.  https://doi.org/10.1159/000345245
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.